PO-1306 apatinib plus capecitabine in patients of recurrent/metastatic and persistent cervical cancer. (August 2021) - Li, J.; Mao, W.; Li, F.; Ran, L.; Chang, J.; Mei, F.; Hu, L.; Du, Y.; Tian, X.; Shan, L.; Liu, M.; Chen, Y.; et al.